Cancer Genetics Announces Distribution Partnership with Nikon Instruments

  Cancer Genetics Announces Distribution Partnership with Nikon Instruments

The Company’s best-in-class cancer diagnostic technologies are becoming widely
             accepted in the global oncology healthcare community

Business Wire

RUTHERFORD, N.J. -- May 8, 2013

Cancer Genetics, Inc.’s (OTCQB: CGIX) (“CGI” or the “Company”) wholly-owned
subsidiary, Cancer Genetics Italia, S.r.l. (“CGI Italia”), has entered into an
agreement with Nikon Instruments S.p.A. (“Nikon”) for the distribution of
oncology-focused DNA Probes intended for fluorescence in situ hybridization
(“FISH”) in the Italian market. This new partnership extends CGI’s global
distribution network and provides more evidence that its best-in-class cancer
diagnostic technologies are becoming widely accepted in the global oncology
healthcare community.

FISH allows for the detection of targeted DNA rearrangements commonly found in
cancers, and is therefore widely used for the diagnosis, outcome prediction
and clinical management of cancer patients. Characterized by a fast turnaround
time, high sensitivity, and the ability to study the cell cycle at different
stages, this methodology represents the leading technology in the molecular
cytogenetics market. With approximately 70,000 tests performed annually in
Italy, this new partnership is expected to rapidly gain market share in Italy
through the offering of a complete solution, including microscopy and
reagents, to cytogenetics and cancer laboratories.

Nikon is ranked among the top microscope manufacturers worldwide, and offers a
wide line of products intended to help laboratories to deliver quality
research and clinical results. Nikon’s microscopes and imaging software
systems, both automated and user-friendly, provide cytogenetics laboratories
with solutions that improve workflow efficiency and reduce subjectivity.
Combined with the CGI Italia DNA-FISH Probes, which allow for more efficient
pinpointing of genetic aberrations, this full solution will allow laboratories
to perform simultaneous multicolor FISH testing with complex image analysis in
academic and clinical settings.

“Through research, CGI has designed and developed a set of outstanding
DNA-FISH Probes for diagnosis of genomic aberrations currently recognized as
essential in clinical practice,” says Raju Chaganti, professor at the Memorial
Sloan-Kettering Cancer Center and founder of the Company. “Joining hands with
Nikon is a great opportunity for both companies, and it advances the cause of
personalized cancer management.”

“Nikon appreciates the great opportunity to distribute CGI Italia DNA-FISH
Probes in the Italian market. This partnership allows us to complete our
instrumentation and consumables line for FISH applications,” says Cristiana
Ricci of Nikon. “Nikon has developed, especially for the Oncology/Hematology
field, a microspots system to investigate FISH on a microchannel, and CGI
Italia’s probes are very important to complete our full solution offer for our

This partnership further enables the Company’s mission to provide clinical
laboratory professionals with robustly designed products for FISH and cancer
diagnostics. While focused initially on the Italian market, this partnership
is expected to expand to other Western European countries. CGI estimates that
over 350,000 FISH-based diagnostic tests are done annually in Western Europe.

About Nikon Instruments S.p.A

Nikon Instruments S.p.A., the Italian subsidiary of Nikon Corporation, Japan,
was founded in 1995. The company’s principal activity is to distribute
diagnostic, research and measurement instruments. The Nikon Instruments
division provides products used for leading-edge research purposes in
clinical, educational usage and training applications. For more information
about Nikon Instruments SPA, please visit

About Cancer Genetics Italia S.r.l.

Cancer Genetics Italia S.r.l. (“CGI Italia”) is a wholly-owned subsidiary of
Cancer Genetics Inc. (“CGI”). CGI Italia manufactures and distributes DNA-FISH
Probes to the clinical and academic communities worldwide. CGI Italia, founded
in 2009 by world-renowned human geneticist R.S.K. Chaganti, is now celebrating
its fourth year of business, and is offering an array of high-quality products
with an oncology focus. Indeed, CGI Italia offers 31 FISH Probes that are CE
marked (also available as RUO – “Research Use Only”) and cover the most
relevant FISH panels for hematological and solid tumors. It should also be
noted that CGI Italia was the first to launch a CE markedALKBreak Apart
Probe in the EU. In addition to commonly used FISH Probes, CGI Italia
developed a proprietary Probe that targets chromosomal aberrations observed in
HPV-associated cancers. We launched the FISH Based HPV-Associated Cancer Test
(FHACT™) intended for cervical cancer in 2012. FHACT™ is currently available
as RUO. CGI Italia news releases and other information are available on the
company's Web site at


RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
Press spacebar to pause and continue. Press esc to stop.